Obesity Clinical Trial
— CAROTOfficial title:
Influence of Weight Loss or Exercise on CARtilage in Obese Knee Osteoarthritis Patients: a Randomized Controlled Trial (CAROT).
Obesity and osteoarthritis (OA) co-exist in an increasing part of the population.
The two diseases intertwine in several ways. The evolution in the population shows a
tendency towards deterioration of both by increasing general age and weight. The two
diseases share pathogenetic features and the development of one disease increases the risk
of the other and may be the onset of a vicious circle.
There is a link between treatments of these two diseases as well. There is now solid (gold)
evidence that by treating effectively the obesity of patients with co-occurring OA, the
functional status is dramatically ameliorated; the short-term results are equal to that of a
joint replacement. The long-term efficacy of a weight loss remains to be shown. OA is
definitely one of many diseases in which obesity must be taken seriously into account when
planning a correct treatment of patients. This trial has two phases, the first (16 weeks)
consisting of a dietary intervention with low-energy diet and the second (52 weeks) a
randomized, three group (each n>50 patients) controlled study of maintenance of weight loss
by either continuing dietary instruction, exercise, or a control group. The hypothesis is
that maintenance of an initially induced weight loss is dependent on attention rather than
any specific therapy.
| Status | Completed |
| Enrollment | 192 |
| Est. completion date | January 2010 |
| Est. primary completion date | January 2010 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 50 Years and older |
| Eligibility |
Inclusion Criteria: - BMI >=30 - Radiographical knee OA - Age >=50 - Spoken Danish - Motivated for weight loss Exclusion Criteria: - Bilateral Alloplasty of the knees - Ongoing or planned surgery - Ongoing or planned alternative weight loss programme - Intellectual disability |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Denmark | The Parker Institute, Frederiksberg Hospital | Frederiksberg |
| Lead Sponsor | Collaborator |
|---|---|
| Henning Bliddal | Cambridge Weight Plan Limited, Oak Foundation, The Danish Rheumatism Association, Velux Fonden |
Denmark,
Bliddal H, Christensen R. The management of osteoarthritis in the obese patient: practical considerations and guidelines for therapy. Obes Rev. 2006 Nov;7(4):323-31. Review. — View Citation
Christensen R, Astrup A, Bliddal H. Weight loss: the treatment of choice for knee osteoarthritis? A randomized trial. Osteoarthritis Cartilage. 2005 Jan;13(1):20-7. — View Citation
Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007 Apr;66(4):433-9. Epub 2007 Jan 4. Review. — View Citation
Roddy E, Zhang W, Doherty M. Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review. Ann Rheum Dis. 2005 Apr;64(4):544-8. Review. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Pain | 16 weeks, 68 weeks | No | |
| Primary | OMERACT-OARSI response criterion | 16 weeks, 68 weeks | No | |
| Secondary | Weight change | 8 weeks, 16 weeks, 68 weeks | No | |
| Secondary | Gait analysis | 16 weeks, 68 weeks | No | |
| Secondary | MRI | 16 weeks, 68 weeks | No | |
| Secondary | Ultrasound | 16 weeks, 68 weeks | No | |
| Secondary | Collagen markers | 16 weeks, 68 weeks | No | |
| Secondary | Metabolic syndrome | 8 weeks, 16 weeks, 68 weeks | No | |
| Secondary | KOOS | 16 weeks, 68 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |